22 September 2020>: Clinical Research
Urachal Carcinoma: Are Lymphadenectomy and Umbilectomy Necessary?
Zhuo Jia ABCDEF* , Xiao Chang ABCD* , Xing Li BC , Baojun Wang AE , Xu Zhang AF*DOI: 10.12659/MSM.927913
Med Sci Monit 2020; 26:e927913
Table 5 Chemotherapy and radiographic response.
Regimen | CR/PR | SD | PD | Total |
---|---|---|---|---|
Cisplatin-based | 4 (30.8%) | 5 (38.4%) | 4 (30.8%) | 13 |
Cisplatin+gemcitabine | 2 (40%) | 1 (20%) | 2 (40%) | 5 |
Cisplatin+paclitaxel | 1 (20%) | 2 (40%) | 2 (40%) | 5 |
Cisplatin+5-FU | 1 (100%) | 0 | 0 | 1 |
Cisplatin+PD-1 inhibitor | 0 | 2 (100%) | 0 | 2 |
Others | 0 | 2 (66.7%) | 1 (33.3%) | 3 |
CR – complete response; PR – partial response; SD – stable disease; PD – progressive disease. |